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Abstract
Huntington's disease (HD) is a devastating, autosomal-dominant neurodegenerative dis-
ease, for which there are currently no disease-modifying therapies. Clinical trials to
replace the damaged striatal medium spiny neurons (MSNs) have been attempted in the
past two decades but have met with only limited success. In this study, we investigated
whether a clonal, conditionally immortalized neural stem cell line (CTX0E03), which has
already shown safety and signals of efficacy in chronic ischemic stroke patients, could
rescue deficits seen in an animal model of HD. After CTX0E03 transplantation into the
quinolinic acid-lesioned rat model of HD, behavioral changes were measured using the
rotarod, stepping, and staircase tests. In vivo differentiation and neuronal connections of
the transplanted CTX0E03 cells were evaluated with immunohistochemical staining and
retrograde tracing with Fluoro-Gold. We found that transplantation of CTX0E03 gave
rise to a significant behavioral improvement compared with the sham- or fibroblast-
transplanted group. Transplanted CTX0E03 formed MSNs (DARPP-32) and GABAergic
neurons (GABA, GAD65/67) with BDNF expression in the striatum, while cortically
transplanted cells formed Tbr1-positive neurons. Using a retrograde label, we also found
stable engraftment and connection of the transplanted cells with host brain tissues.
CTX0E03 transplantation also reduced glial scar formation and inflammation, as well as
increasing endogenous neurogenesis and angiogenesis. Overall, our results demonstrate
that CTX0E03, a clinical-grade neural stem cell line, is effective for preclinical test in HD,
and, therefore, will be useful for clinical development in the treatment of HDpatients.
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1 | INTRODUCTION
Huntington's disease (HD) is a devastating genetic disease, affecting
approximately 5 out of every 100 000 people in the United States,
Europe, and Australia.1 In HD, one of the earliest and major patholo-
gies is the degeneration of the medium spiny neurons (MSNs) in the
striatum due to the cytotoxic effects of mutant huntingtin protein.
Coupled with pathology at other sites, especially the cortex, MSN
degeneration leads to the classical clinical trial of abnormal move-
ments, psychiatric problems, and cognitive deficits. Currently, there is
no cure or disease-modifying therapy available for HD patients.
Therefore, stem cells have long been considered a promising thera-
peutic resource for HD to replace the lost striatal MSNs as well as to
modulate several pathogenic pathways through paracrine release of a
range of neuroprotective and immune modulatory factors.2 A signifi-
cant number of stem/progenitor cells have been studied that include
embryonic stem cells; multipotent progenitor cells from the embryo or
fetus, which are already partially committed to a neural lineage; cells
from the umbilical blood; autologous or allogenic adult stem cells from
various tissues; and finally induced pluripotent stem cells.3,4 Among
them, neural stem cells (NSCs) have been regarded as a promising
option to treat HD as they can survive and differentiate into proper
neuronal cell types in vivo. Numerous studies have indicated that
NSC can have the potential to replace the damaged MSNs and make
functionally active connections to the host neuronal network. Both
systemic injection of human NSC in the quinolinic acid (QA) rat
model5 and intrastriatal injection of human NSC in the 3-NP rat
model6 demonstrated reduced striatal damage and improved locomo-
tor activity. Transplanted mouse NSC from neurospheres could sur-
vive in R6/2 transgenic HD model.7 More recently, intrastriatal
transplantation of mouse induced pluripotent stem cell-derived NSCs
(iPSC-NSC) in YAC128 mice also ameliorated locomotor deficits and
differentiated into MSNs.8 Although various preclinical studies using
different types of NSC in different rodent HD models have indicated
its potential therapeutic benefits, no one has tested the efficacy of
clinical-grade human NSC, such as CTX cells so far. Clinical trials of
intracerebral transplantation using human fetal striatal tissues have
demonstrated limited benefits and survival.2
A sustainable source of ethically approved, safe, and potent
stem cells is one of the most important requirements for the devel-
opment of an effective cell therapy, and this holds for HD as well.
CTX0E03 (CTX) is a GMP-manufactured conditionally immortalized
human NSC line9,10 under current clinical trial (PISCES III,
NCT03629275) and may serve as a reliable source of NCS for pro-
viding beneficial effects in preclinical HD studies. Direct intracere-
bral implantation of CTX cells in a rodent middle cerebral artery
occlusion (MCAO) model of stroke demonstrated reproducible
recovery of lesion-associated behavioral deficits by stimulating
reparative mechanisms, such as angiogenesis and neurogenesis in
the lesion site.9,11 When CTX cells were placed into the ischemic
brain, engulfment of apoptotic cells by macrophages promoted M2
polarization, resulting in tissue repair.12 Based on this mechanistic
understanding, it has been hypothesized that these cells may have
benefits in other diseases of the brain, such as HD. To test this
hypothesis, we investigated the effect of CTX in the QA-lesioned
rat model of HD. In this model, excitotoxic lesion leads to degenera-
tion of the DARPP-32 positive cells and an inflammatory response,
which correlates with the typical loss of MSNs and neu-
roinflammation seen in HD patients at postmortem.13
2 | MATERIALS AND METHODS
2.1 | Cell preparation
2.1.1 | Control fibroblast cell line
Embryonic fibroblasts were obtained from aborted human embryos
following approval by the Institutional Review Board of CHA
Gangnam Medical Center (Seoul, Korea). Fibroblasts were
maintained in Dulbecco's modified Eagle's medium (DMEM) high
glucose (Welgene, Korea), supplemented with 10% fetal bovine
serum (Invitrogen) and 1% penicillin/streptomycin (Sigma-Aldrich)
grown on 0.2% gelatin-coated culture dish. For the transplantation
of fibroblasts, they were dissociated using 0.25% trypsin-EDTA and
resuspended at 100 000 cells/μL in DMEM high glucose with
30 μM Y-27632 (Tocris) following centrifugation at 1200 rpm for
3 minutes.
2.1.2 | CTX (CTX0E03) drug product
CTX is of human origin and was established as a clonal cell line
by conditional immortalization with c-mycERTAM.14 CTX0E03/06T
passage 23 was revived from cryopreservation with a viability of
96%. CTX cells were cultured in a serum-free medium (RMM)
Significance statement
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Huntington's disease (HD). The results demonstrated that
intracerebral transplantation of CTX0E03 cells can lead to
significant improvements in the behavioral and pathological
deficits of a rodent model of HD by both cell replacement
and host cell regeneration mechanisms. Therefore, this
study provides a strong basis for clinical development of
these cells to treat HD patients in the future.
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supplemented with epidermal growth factor (EGF, 20 ng/mL,
Peprotech), basic fibroblast growth factor (bFGF, 10 ng/mL,
Peprotech), and 4-hydroxytamoxifen (4-OHT, 10 mM, Sigma) on
laminin (20 μg/mL, or 2.28 μg/cm2 AMS Biotech) coated vessels
in an incubator at 37C in a humidified atmosphere containing
5% CO2. The cells were fed every 2 to 3 days and passaged once
the cells were 70% to 80% confluent. CTX drug product
(DP) cells was prepared from two T-500 flasks, seeded and
grown to 85% confluency for harvest at passage 32. For cell har-
vest, the medium was aspirated and the adherent cells washed
with HBSS (–Ca2+/Mg2+). Cells were then dissociated with
TrypZean/EDTA (BE02-034E Lonza) for 5 minutes before the
addition of the DTI/Benzonase inhibitor (Invitrogen R007100;
Merck 1.01654.0001). Cells were collected from flasks with
20 mL of RMM+GF+4-OHT and centrifuged at 500g (eg,
1500 rpm) for 5 minutes at ambient temperature. The cell pellet
was resuspended in RMM+GF for trypan blue viability and cell
counting, then centrifuged and resuspended in 57.7% HTS
(HypoThermosal)-FRS/DMEM: F12 at a density of 50 000 cells/μL
in HTS-FRS (BioLife Solutions, 101102). Finally, CTX (CTX0E03)
DP (CTX0E03/07 passage 32) was prepared at ReNeuron
(Guildford, UK) and shipped frozen under controlled conditions to
the CHA Stem Cell Institute (Republic of Korea). For use, a vial
of CTX0E03 cells was removed from <−135C storage and
thawed immediately in a water bath at 37 (±1)C for 1 minute
before placing on ice for a maximum of 4 hours. Before each
use, cells were gently triturated using a pipette. As for the
medium control, HTS-FRS was used.
2.2 | QA model of HD and CTX cell transplantation
Animal experiments were performed in accordance with the CHA Uni-
versity Institutional Animal Care and Use Committee (IACUC140013).
Male Sprague Dawley rats (Orient Bio Ltd, Seongnam, Korea) were
group housed (12:12, light:dark cycle) and fed ad libitum. At 8 weeks
of age, 50 rats received a single, unilateral injection of 2 μL volume
containing 120 nmol QA (2,3-pyridinedicarboxylic acid, Sigma) into
the right striatum-stereotaxic coordinates AP = +1.0, ML = +2.5 mm,
DV = −5.0 mm. One week after QA lesioning, animals that developed
behavioral deficits in the rotarod (the time spent on the rotarod
<60 seconds), stepping (the left step numbers <1), and staircase (the
number of pellets taken <4) tests were selected for cell transplanta-
tion. A total of 32 QA-lesioned rats underwent stereotaxic injection
into the striatum and the cortex with each site receiving 1 μL of the
“transplant material” which contained either Media (N = 11, Sham
group), 1 × 105/μL Human Fibroblasts (N = 9), or 1 × 105/μL CTX cells
(N = 12). This cells were delivered at the coordinates, AP = +1.5,
ML = +2.5 mm, DV = −5.0 mm for the striatum and AP = −0.5,
ML = +1.5 mm, DV = −2.0 mm for the cortex. All animals received
immunosuppressant, Cyclosporine A, by the intraperitoneal route
starting at a dose of 10 mg/kg, 2 days prior to the transplantation
surgery and then 5 mg/kg daily after surgery until sacrifice
(Supporting Information Figure S1).
2.3 | Retrograde labeling with Fluoro-Gold
At 12 weeks post-transplantation, two rats from the CTX-
transplanted group were injected with 0.5 μL volume of 4% Fluoro-
Gold (FG) into the globus pallidus using the stereotaxic coordinates
AP = −1.0, ML = +2.5 mm, DV = −6.0 mm.15 Animals were sacrificed
1 week after FG injection and processed for immunohistochemistry.
2.4 | BrdU administration
At 12 weeks post-transplantation, three rats from each of the Sham
(Media), Fibroblast, and CTX-transplanted groups were injected with
BrdU (Cat no B5002, Sigma-Aldrich) at a dose of 50 mg/kg twice
daily, for 3 days by the intraperitoneal route.16 After 3 days of BrdU
administration, animals were sacrificed and processed for
immunohistochemistry.
2.5 | Behavioral testing
2.5.1 | Rotarod test
The rotarod test was performed at 0 (baseline), 2, 4, 6, 8, 10, and
12 weeks post-transplantation to assess motor coordination. Baseline
was set before cell transplantation, which was performed 7 days after
QA lesioning. Rats were placed on the rotating rod with an accelerat-
ing speed of 4 to 40 rpm over a period of 3 minutes with a 15 minutes
rest period between trials.17 The time taken for each rat to fall from
the rod was recorded over three separate trials and the mean laten-
cies were used for analysis. Rats underwent rotarod test training com-
prising of three trials per day over three consecutive days prior to QA
lesioning.18 Rats spent on the rotating rod for less than 60 seconds
were selected for cell transplantation.
2.5.2 | Stepping test
The stepping test was performed at 0 (baseline), 2, 4, 6, 8, 10, and
12 weeks post-transplantation to assess akinesia. Rats were held on a
tabletop in a forelimb stance, with their body at nearly 90 on the
table. Once the rats appear relaxed, they were pushed forward to
move along the surface of the tabletop. We counted the number of
right and left steps while moving across the surface. This test was
always performed by the same operator and rats were familiarized
with the experimenter's grip prior to testing. During the test, the num-
ber of forepaw placements was counted as the rat was moved slowly
in both forehand and backhand directions along the edge of a table
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over a distance of 90 cm in a 5-second period.19 Rats used the left
step more than one time were not selected for cell transplantation.
2.5.3 | Staircase test
The staircase test was performed once a day for three consecutive
days at time 0 (baseline), 2, 4, 6, 8, 10, and 12 weeks post-
transplantation to provide a quantifiable measure of fine motor
reaching skill in the left affected limb only. The staircase consists of a
two-compartment box with a raised platform and two stairs in the
narrow compartment. The left steps on the stairs in the narrow
compartment can be reached only with the left paw and the right
steps only with the right paw. The eight wells of each step are filled
with five 45 mg food pellets. Food was removed from holding cages
24 hours prior to testing and replaced thereafter. Rats underwent a
10-minutes test period, during which time the number of food pellets
retrieved with the affected limb was measured. Rats underwent a
training period for the staircase test prior to QA lesioning. Rats
that took less than four food pellets were selected for cell
transplantation.
2.5.4 | Statistical analysis for behavioral test
measurements
Analysis of the behavioral data from the rotarod, stepping, and stair-
case tests was performed using Statistical Analysis System Program
(Enterprise 4.1; SAS Korea). The performance measured from the
three behavioral tests was analyzed according to the PROC MIXED
procedure. For post hoc analysis, Fisher's least significant difference
(LSD) was used.
2.6 | Immunohistochemistry
2.6.1 | Tissue preparation
At 13 weeks post-transplantation, rats were transcardially perfused with
heparinized (5 U/mL) saline (NaCl 0.9%) followed by 4% buffered para-
formaldehyde. Brains were removed from their skulls and fixed overnight
in 4% buffered paraformaldehyde at 4C to 8C, then, transferred to
30% sucrose phosphate buffered saline (PBS) solution for 3 days until
they sank and they were then frozen in OCT compound. Forty-microme-
ter thick coronal cryosections prepared using a cryotome (CM3050,
Leica, Germany) were stored in cryoprotective solution (40% glycerol,
40% ethylene glycol, 0.2 M PBS) at −20C until use.
2.6.2 | CTX cell survival
Cell survival was evaluated with seven free-floating sections from
each of the 12 CTX injected brains. A human-specific nuclei (hNu)
antibody (1:200, MAB1281, Chemicon) was used with conventional
single label DAB (3,30-diaminobenzidine) immunohistochemistry to
detect CTX cells.
2.6.3 | CTX cell differentiation
CTX differentiation was analyzed from the transplanted rat brains.
Dual label fluorescence immunohistochemistry was performed using
antibodies to the human-specific nuclei20 (1:200, MAB1281,
Chemicon) or human-specific mitochondria (hMito; 1:200, AB3598,
Chemicon) to detect CTX cells, combined with differentiation markers
of DARPP-32 (1:100, #2306, Cell Signalling) for MSNs, GABA
(1:1000, A2052, Sigma) and GAD 65/67 (1:200, AB1511, Chemicon)
for GABAergic neurons, Tbr1 (1:200, ab31940, Abcam) and BDNF
(1:200, Ab1534, Chemicon) for cortical neurons. Goat antimouse IgG-
conjugated Alexa 555 (1:200, Molecular Probes) and goat antirabbit
IgG-conjugated Alexa 488 (1:200, Molecular Probes) were used as
secondary antibodies for detection and visualization, and a DAPI
counterstain was applied. Images were captured using a confocal
laser-scanning microscope imaging system (Leica TCS SP8, Germany).
2.6.4 | Host brain responses
Host brain responses were investigated on the transplanted rat brains.
Based on the DAB immunohistochemistry, CTX-transplanted animals
showing a good graft survival with average behavioral scores were
chosen (N = 3). As for the other experimental groups, three indepen-
dent animals with average scores were chosen from the Sham (media,
N = 3) and Fibroblast (N = 3) groups. Three independent sections from
each animal (ie, a total of nine sections from three brains of each
experimental group) were used for immunohistochemical (IHC) analy-
sis per each marker. Fluorescence immunohistochemistry was per-
formed on free-floating sections using primary antibodies to
investigate the glial scar with GFAP IHC (1:200, 556327, BD Biosci-
ence), the microglial response with Iba-1(1:100, 019-19741, Wako),
the macrophage response with ED1 (1:100, MCA1957GA, Serotec),
the inflammatory M1 macrophage phenotype with iNOS (1:100, sc-
650, Santacruz), the anti-inflammatory M2 phenotype with CD206
(1:100, sc-34 577, Santacruz), neurogenesis with DCX (1:200, #4604,
Cell Signalling) and BrdU (1:100, 555 627,BD Pharmigen), and angio-
genesis with Reca-1 (1:200, ab9774, Abcam). Goat antimouse IgG-
conjugated Alexa 555 (1:200, Molecular Probes) and goat antirabbit
IgG-conjugated Alexa 488 (1:200, Molecular Probes) were used as
secondary antibodies, and a DAPI counterstain was applied. Images
were captured using a confocal laser-scanning microscope imaging
system (Leica TCS SP8). For BrdU immunohistochemistry, tissue
sections underwent pretreatment in 0.1 M sodium citrate buffer for
30 minutes at 100C before incubation with the antibody. Host
responses were quantified using the ImageJ software (NIH). Manual
counts were used for collection (ED1, iNOS, CD206 positive cells for
macrophage responses; DCX, BrdU-positive cells forneurogenesis,
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and Reca-1 positive blood vessels for angiogenesis) or measurement
of the area of staining (GFAP for glial scar and Reca-1 for angiogene-
sis) within three separate 100 μm2 regions of interest. For the glial
scar, the region of interests (ROIs) of macrophage response and angio-
genesis were sampled within the striatum and for neurogenesis, and
the same ROIs were applied to each brain within the subventricular
zone (SVZ). Data (counts or area) were statistically analyzed using the
one-way analysis of variance (SigmaPlot).
3 | RESULTS
3.1 | Behavioral improvement following
transplantation of CTX cells
To evaluate the therapeutic effect of CTX cells on animal model, we
transplanted them into QA-lesioned rodent model of HD (N = 12).
We used media (N = 11, Sham group) and human fibroblasts (N = 9,
Fibroblast group) as control groups. On the rotarod, stepping and
staircase tests, the CTX treated group exhibited significantly improved
performance compared with Sham and Fibroblast only grafted groups,
between 8- and 12-weeks post-transplantation (Figure 1).
3.2 | Survival, distribution, and differentiation of
CTX cells in QA-lesioned brain
To prevent or reduce immune rejection of human-derived CTX cells
when transplanted into a rat HD model, immunosuppressant,
Cyclosporine A, was administered intraperitoneally, starting at a dose
of 10 mg/kg, 2 days prior to the transplantation surgery and then
5 mg/kg daily after surgery until sacrifice. To determine whether CTX
cells were integrated into the QA-lesioned host brain following trans-
plantation, we performed histological analysis. Serial sections col-
lected from the 12 CTX-implanted brains, in the range of AP: +1.6 mm
and −1.2 mm, were subject to brightfield immunohistochemistry using
a human-specific nuclei antibody (hNu) to detect surviving CTX cells
(Figure 2). We detected CTX cells in the transplanted brains at
13 weeks postimplantation that were mostly located close to the site
of transplantation, in the range of AP: +0.8 mm and −0.8 mm, in the
lesioned striatum (Figure 2) as well as in the overlying cortex. Quantifi-
cation of CTX survival in the striatum showed that over 10% of the
original number of transplanted cells were present at 13 weeks post-
transplantation. Sections from CTX-transplanted brains were also sub-
ject to double-label fluorescence immunohistochemistry to determine
the level of neural differentiation within the graft. To identify the
CTX-derived cells in the transplanted animals, we further performed
immunohistochemistry with a series of antibodies against DARPP-32
(MSN), GABA and GAD 65/67 (GABAergic), BDNF and Tbr1 (gluta-
matergic). Microscopic analysis revealed that some surviving CTX cells
in the lesioned striatum expressed markers specific for striatal neuro-
nal subtypes, such as DARPP-32, GABA, and GAD 65/67 (Figure 3). In
addition, some CTX cells in the striatum expressed the neurotrophic
factor, BDNF (Figure 2). Only CTX cells transplanted into the cortex
expressed Tbr1, a marker specific for cortical glutamatergic neurons
(Figure 4).
F IGURE 1 CTX cells significantly improve the behavioral deficits
induced by quinolinic acid (QA) lesioning of the striatum. Marked
improvement of locomotor activity was observed in the QA-lesioned rats
transplanted with CTX between 8 and 12 weeks post-transplantation
(**P < .001 Sham vs CTX; ##P < .001 Fibroblast vs CTX) on rotarod
(A) and stepping (B) tests. In the staircase test (C), significant behavioral
improvement was observed in the QA-lesioned rats with CTX between
8 and 12 weeks after transplantation (*P < .05 Sham vs CTX; #P < .05
Fibroblast vs CTX). Prescore represents the animals before receiving QA
and the baseline score represents 7 days after QA lesioning. Subsequent
scores represent animals after CTX transplantation
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3.3 | Neuronal connection between transplanted
CTX cells and FG+ host brain cells
Microscopic analysis revealed that CTX cells in the striatum showed
uptake of FG, which had been injected into the globus pallidus
(Figure 4), indicating that CTX cells have established striatal-pallidal
connections.
3.4 | Reduction of gliosis and host immune
responses following transplantation of CTX cells
First, we investigated glial scar formation. Brain sections of three rep-
resentative animals from each experimental group were subject to
GFAP immunohistochemistry to demonstrate glial scar formation.
GFAP staining, quantified by image analysis in the lesioned striatum,
F IGURE 2 CTX cells can survive and
differentiate into striatal neurons in the striatum
of quinolinic acid (QA)-lesioned brain 13 weeks
after transplantation. A, Widespread distribution
of survived CTX cells were detected using a
human nuclei antibody (hNu) and visualized with
DAB (3,30-diaminobenzidine) in the QA-lesioned
striatum. Scale bar = 50 μm. B-E, Neuronal
differentiation of CTX cells transplanted into the
striatum (arrows) was identified by hNu
colocalized with neuronal markers, including
DARPP-32 (B), GABA (C), GAD 65/67 (D), and
BDNF (E). Scale bar = 50 μm
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was shown to be significantly reduced in CTX-implanted brains com-
pared with Sham (Media) and Fibroblast treatment (Figure 5A),
although we observed small portions of grafted CTX cells turned into
GFAP-positive cells (Supporting Information Figure S2). Second, we
examined the microglial response. Brain sections from all three treat-
ment groups were subject to IBA-1 immunohistochemistry and it was
significantly reduced in the CTX-implanted brains compared with
Sham (Media) and Fibroblast treatment (Supporting Information
F IGURE 3 CTX cells implanted in the cortex can differentiate into cortical neurons. Colocalization (yellow) of hNu and Trb1 demonstrates
neuronal differentiation of CTX cells in the cortex 13 weeks after transplantation (arrows). Scale bar = 50 μm
F IGURE 4 CTX cells can establish striato-pallidal connection in the quinolinic acid (QA)-lesioned striatum. Colocalization (yellow) of Fluoro-
Gold (FG) and human nuclei in CTX cells (arrows) within the stratum suggests some restoration of local circuitry. Scale bar = 50 μm
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Figure S3). Finally, we quantified the macrophage response to the
lesion and graft. Brain sections from all three treatment groups were
subject to double-label immunohistochemistry using a cocktail of anti-
ED1 and anti-iNOS or anti-ED1 and anti-CD206 antibodies to detect
pro- and anti-inflammatory macrophage phenotypes, respectively.
Quantification of these cell types in the lesioned striatum showed a
significant reduction and increase in iNOS/ED1 (M1 proinflammatory)
and CD206/ED1 (M2 anti-inflammatory) cells, respectively, compared
with the Sham (media) and Fibroblasts groups (Figure 5B,C).
3.5 | Increased endogenous neurogenesis
following transplantation of CTX cells
Brain sections collected from animals (ie, all three treatment groups)
previously administered with BrdU were subject to double-label
immunohistochemistry with anti-BrdU and anti-DCX antibodies.
Quantification of BrdU+, DCX+, and DCX+/BrdU+ cells showed an
increase in all these phenotypes in the SVZ of CTX-implanted brains
compared with those of the Sham (media) and Fibroblast groups
(Figure 6).
3.6 | Increased endogenous angiogenesis following
transplantation of CTX cells
Brain sections from all treatment groups were subject to RECA-1
immunohistochemistry to examine vascularization. RECA-1 staining,
quantified by image analysis, and counts of branch point and
microvessels in the lesioned striatum were shown to be significantly
increased in the CTX-implanted brains compared with the Sham
(Media) and Fibroblast treated brains (Figure 7).
4 | DISCUSSION
In this study, we explored the therapeutic effect of CTX, a condition-
ally immortalized GMP-manufactured human NSC, in the QA model
of HD using various behavioral and IHC analyses. Injection of QA, an
intrinsic neuroactive metabolite of the kynurenine pathway, can
induce degeneration of striatal GABAergic projection neurons while
preserving striatal afferents, which resembles the neuropathologic
condition in HD patients.21,22 QA-lesioned rats is one of the most
well-characterized HD models for motor and cognitive symptoms,
F IGURE 5 CTX cells decrease gliosis and proinflammatory responses in the quinolinic acid (QA)-lesioned striatum. A, GFAP staining was
significantly reduced in CTX-implanted brains compared with Sham (Media) and Fibroblast (FB) injected brains (CTX vs Sham P = .004; CTX vs FB
P = .014). Scale bar = 50 μm. B, CTX cells reduce a M1 proinflammatory phenotype of macrophage in the QA-lesioned striatum. The percentage
of iNOS/ED1 was reduced in CTX treated brains compared with Sham (Media) and Fibroblast grafted brains (CTX vs Sham P < .001, CTX vs FB
P = .017). C, CTX cells increase an M2 anti-inflammatory phenotype in the QA-lesioned striatum. CD206/ED1 increased in CTX treated brains
compared with Sham (Media) and Fibroblast injected brains (CTX vs Sham P < .001, CTX vs FB P < .001). Scale bar = 50 μm
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F IGURE 6 CTX cells promote neurogenesis in the quinolinic acid (QA)-lesioned brain. Compared with Sham (Media) and Fibroblast injected
brains, the proportion of both BrdU and DCX stained cells was increased markedly in the SVZ of CTX treated brains (BrdU/DAPI CTX vs Sham
P < .001, CTX vs FB P < .001; DCX/DAPI CTX vs Sham P < .001, CTX vs FB P = .002). The percentage of DCX expressing cells in BrdU-positive
cells in the SVZ was also significantly increased in CTX treated brains (DCX/BrdU CTX vs Sham P = .025, CTX vs FB P = .029). Scale bar = 100 μm
F IGURE 7 CTX cells promote angiogenesis in the quinolinic acid (QA)-lesioned brain. RECA-1 staining demonstrates that the number of
branch points and microvessels was all significantly increased in CTX-implanted brains compared with Sham (Media) and Fibroblast injected
brains (P < .001 CTX vs Sham; P < .001 CTX vs FB; branch points P = .019 CTX vs Sham; P < .001 CTX vs FB; microvessels P < .001 CTX vs Sham;
P < .001 CTX vs FB). Scale bar = 50 μm
944 PRECLINICAL EFFICACY OF CTX CELLS IN QA-LESIONED HD RATS
including decreased spontaneous locomotion, profound impairment in
paw reaching test and place-learning deficit in the Morris water
maze,23-25 and have been used as a useful model to evaluate the effi-
cacy of stem cell transplantation in terms of behavioral and pathologi-
cal changes.26
Rotarod, stepping, and staircase tests were employed to assess
motor coordination, akinesia, and fine motor reaching skills, respec-
tively, and the pre- and post-lesioning behavioral deficits following
CTX cell transplantation were analyzed compared to those following
sham and fibroblast transplantation. The effect of CTX transplantation
was also evaluated in terms of cell survival, differentiation, and con-
nectivity as well as their effects on innate regenerative processes such
as angiogenesis and neurogenesis and the inflammatory response. As
for the target sites for CTX transplantation, the cerebral cortex in
addition to the striatum was selected because cortical cell loss can
also contribute to motor symptoms, which has been ascribed primarily
to the striatum in HD patients.27,28 At the same time, the in vivo
potential of CTX cells to differentiate into the region-specific neurons
can be evaluated through this approach.
Behaviorally, we found that the QA-lesioning–induced behavioral
deficits were partially reversed between 8 and 12 weeks after CTX
implantation (Figure 1). Although non-QA-lesioned animals would be
useful as an intertrial test to demonstrate the behavior of “normal” rats,
CTX-implanted rats performed significantly better on all three different
behavioral tests employed at these time points, when compared with
sham (media) and fibroblast transplants. This delay in benefits is in line
with what has been reported previously with CTX transplantation in
chronic stroke model.29 This suggests that the capability of CTX may be
attributed to progressive replacement of injured neurons and/or modu-
lation of the host environment to promote regenerative mechanisms
rather than through some direct lesion modifying effect.
As shown from IHC analyses, CTX cells can survive, express
BDNF, and differentiate into the region-specific neurons in the stria-
tum (DARPP-32, GAD65/67) (Figure 2) and in the cortex (Tbr1,
Figure 3) in vivo at 13 weeks after transplantation. The presence of
FG within the surviving CTX also suggests that these cells can form
local circuits (Figure 4). It will be very useful to perform electrophysi-
ology in the future, to confirm the neuronal integration and action
potentials of the transplanted cells. All these results suggest that CTX
cells have a significant potential as a cell replacement therapy for HD.
Previous reports demonstrated that BDNF-overexpressing NSCs
are neuroprotective in the MCAO model of stroke.19 Likewise, the
current CTX-transplanted HD model also expressed BDNF, suggesting
that production of BDNF from CTX provided neuroprotective effects
in HD. This may also explain some of the other changes we observed
in the host brain following transplantation.
In neurodegenerative diseases, including HD, the astrocytic and
microglial responses are thought to have a role in driving the disease
process.30,31 In the present study, we found that CTX cells can modu-
late a broad spectrum of host cellular responses in a positive way to
promote regeneration and repair. In particular, both astrocyte and
microglia responses were significantly reduced in brains implanted with
CTX. Astrocytes are known to form a glial scar to isolate injured tissue
for protecting neurons from contact-induced apoptosis, and microglia
clean up the site of injury by phagocytosis of cellular debris and dead
neurons.32,33 We found that CTX transplantation can lead to a signifi-
cant decrease of glial scar formation (Figure 5A). Interestingly, we also
observed small portions of grafted CTX cells turned into GFAP-positive
astroglia cells (Supporting Information Figure S2), suggesting a contribu-
tion of graft-derived glial cells to the rescue of HD phenotypes.34 CTX
transplantation was also shown to modulate macrophages in the
lesioned striatum. Macrophages can change their characteristics in
response to environmental changes, which result in a dual role in the
response to injury.35 The phagocytic M1 phenotype functions like
microglia to remove the post-injury cellular debris, while the M2 type
anti-inflammatory phenotype secretes a cocktail of anti-inflammatory
mediators that promote wound repair. In the chronic inflammatory
environment, the persistent M1 phenotype leads to increased secretion
of proinflammatory mediators and enzymes that cause further tissue
destruction and injury. Importantly, polarization of M1 to an M2 pheno-
type is a key event for the resolution of inflammation and the initiation
of reparative mechanisms.36 We found that CTX led to an M1 to M2
polarization as demonstrated by a predominance of a CD206 M2 phe-
notype and a reduction in the inflammatory iNOS M1 phenotype in the
lesioned striatum implanted with CTX (Figure 5B,C). Taken together, it
is evident that CTX implantation can not only replace lost cells and
make connection but also has the ability to reduce the responses of
several cell types involved in neuroinflammation.
Finally, we were able to show that CTX implantation promotes
other reparative mechanisms in the brains of HD model. IHC staining
using BrdU combined with DCX (a marker of migrating neuroblasts)
showed a significant increase in the subventricular zone (SVZ) of CTX-
transplanted brains (Figure 6), which is in line with a previous report
showing that there is a significant increase in DCX/Ki67 neuroblasts
in CTX-implanted MCAO brains.37 In addition, we found that blood
vessel formation is significantly increased, as seen with Reca1
staining, in CTX-transplanted brains (Figure 7), again in line with what
is seen with these cells in stroke models.11
5 | CONCLUSION
We have shown that CTX implantation is an effective treatment in
the QA model of HD and works through multiple mechanisms, includ-
ing cell replacement. Transplantation of CTX cells improved lesion-
associated behavioral deficits on the rotarod, stepping, and staircase
tests. Characterization of transplanted CTX demonstrated that they
could undergo region-specific differentiation in the striatum and the
cortex and establishment of striato-pallidal connections with the host
tissue. Moreover, CTX transplantation reduced the local host inflam-
matory responses and promoted regenerative mechanisms such as
angiogenesis and neurogenesis. Although additional analysis using
transgenic HD mouse models will be useful,38 given all these current
results and the fact that the cell has already been subject of clinical tri-
als in stroke, CTX offers great potential as treatment for patients
with HD.
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